- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05041023
Experience of Relatives and Intensive Care Units Caregivers of Controlled Donation After Circulatory Death (CARE-M3)
Experience of Relatives and Caregivers of Death in ICU After the Withdrawal of Life-sustaining Therapies, Associated With an Organ Procurement Procedure (Controlled Donation After Circulatory Death).
Controlled donation after circulatory death (cDCD) refers to organ donation (OD) from patients whose death is defined using circulatory criteria and from whom circulatory death occurs after a planned withdrawal of life-sustaining therapies (WLST) in intensive care units (ICUs). During cDCD, the patient is still alive while OD process is being discussed and organized. Caregivers can be particularly uncomfortable in this scenario. In the specific context of cDCD, developing knowledge on the perceptions and experiences of relatives and ICU caregivers regarding OD is crucial but remains poorly investigated.
Investigators propose to conduct a prospective multicentric observational research to better understand relatives' and ICU caregivers' experience of cDCD. Better understanding their perceptions and experiences will enable to develop interventions to support and guide them throughout this practice.
Study Overview
Status
Intervention / Treatment
Detailed Description
While withdrawal of life-sustaining therapies (WLST) decision occur significantly more frequently in intensive care units (ICUs), controlled donation after circulatory death (cDCD) evolves end-of-life care and produces a new end-of-life (EOL) model: EOL care now includes the opportunity to donate organs and tissues after death. During cDCD, the patient is still alive while OD process is being discussed and organized. Caregivers can be particularly uncomfortable in this scenario where EOL care and OD in effect overlap. Thus, the implementation of a cDCD program in France, as elsewhere, raised the issue of the potential impact of OD on WLST decision-making processes and EOL practices (particularly sedation). As other countries, the national protocol is nonetheless clear that the decision for WLST must be made in the bests interest of the patient and independent of any consideration of OD, and the donation pathway must not change EOL care. The challenge is not only to identify patients suitable as potential donors but also to provide support to grieving families and to make HCPs comfortable with OD in this particular context. In the specific context of cDCD, developing knowledge on the perceptions and experiences of relatives and ICU caregivers regarding OD is crucial but remains poorly investigated.
Investigators propose to conduct a prospective multicentric observational research to better understand relatives' and ICU caregivers' experience of cDCD.
A relative and/or at least two caregivers (1 physician and 1 or 2 paramedics) are included for any situation of death of a patient in ICU following a decision to withdraw LST and for which OD has been discussed with the relatives, whether or not the organ procurement finally occurred.
Two situations are distinguished:
- WLST without OD possibility: the WLST is initiated while OD is no longer considered for one of the following reasons: medical unsuitability, expressed intend not to be a donor or family refusal, legal issues, logistical problems, hemodynamic instability.
- WLST with OD possibility: the WLST is initiated while OD is still considered, whether or not OD finally occurs for one of the following reasons: circulatory death declared > 180 minutes, excessive warm ischemia time due to normothermic regional perfusion dysfunction or hypoperfusion.
At the time of the discussion about OD with the relatives :
- The screening for inclusion will be done.
- If 1 relative volunteers to participate in the study (non-opposition noted by the investigator), the situation is included in CARE-M3 "relative" section.
- If no relatives volunteer to participate in the study, the situation can be included in CARE M3 for the caregiver section after the patient's death.
After the patient death, wether or not OD occurs:
- 3 caregivers (1 physician and 2 paramedics) can be included. These are the caregivers who are present at the time the WLST is initiated.
- If at least two caregivers volunteer to participate in the study, the situation is included in CARE-M3 caregiver section.
Objectives concerning the relatives
- Primary objective: to study their risk of developing symptoms of post-traumatic stress disorder in the months following the patient's death.
- Secondary objectives: assessment of symptoms of anxiety, depression, complicated grief, assessment of understanding of the decision process to withdraw LST and the cDCD procedure.
Objectives concerning the ICU caregivers
- Primary objective: to study their risk developing anxiety relating to the event.
- Secondary objectives: evaluation of the impact of the cDCD procedure on the WLST decision-making process, end-of-life practices, support at the end-of-life (EOL) and quality of the EOL.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75010
- APHP - Lariboisière hospital - réanimation chirurgicale
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
The relatives of patients who have died in ICU are the first attendant of the patient at the end-of-life EOL. During this procedure, relatives are particularly solicited because they are strongly involved in the decision-making process. The most involved relative in the relationship with the resuscitation team will be asked to participate in the study.
Caregivers included in the study are caregivers from ICU who are present at the time the withdrawal of life-sustaining therapies WLST is initiated: at least 1 physician and 1 or 2 paramedics.
Description
Inclusion Criteria:
Any situation of anticipated death of a patient in Intensive Care Unit ICU due to circulatory arrest:
- For which a decision to withdraw Life-Sustaining Therapies LST was taken under the Claeys-Leonetti law, notified to relatives and accepted by relatives
- With a first evaluation by the hospital coordination of organ and tissue removal identifying the patient at the end of life as a potential donor: patient identified under the age of 70, with no absolute contraindication to organ removal in the context of an M3 procedure
- For which Organ Donation OD has been discussed with the relatives, whether the OD finally occurred.
- Relative and/or caregiver who has given non-objection to the use of the data.
Exclusion Criteria:
- None
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Relative volunteers
For each situation of death of a patient in ICU following a decision to withdraw LST and for which OD has been discussed with the relatives, a relative can be included after information and acceptance of the study.
One relative per situation can be included : the most involved personn in the relationship with the resuscitation team.
|
Relatives are assessed by phone calling with an experienced psychologist at 3 and 6 months after patient's death. Relatives answer to self-questionnaire and 3 scales. Furthermore, 20 of them are offered to participate in a semi-structured interview with an experienced psychologist, within 6 months to 1 year following the patient's death. |
|
Caregivers
For each situation of death of a patient in ICU following a decision to withdraw LST and for which OD has been considered, 2 to 3 caregivers who are present at the time the WLST is initiated can be included (1 physician and 1 or 2 paramedics).
|
Caregivers are self-evaluated within 72 hours after death by questionnaire survey, whose results will remain confidential to the center that included the situation. Furthermore, 20 of them (10 medical staff and 10 paramedical staff and / or until saturation) are offered to participate in a semi-structured interview with an experienced psychologist. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hetero-evaluation of the relative using the IES-R scale
Time Frame: 3 months after patient's death
|
Hetero-evaluation of the relative with the IES-R score (Impact of.
Event Scale - Revised score).
Assessment is performed by telephone interview with an experienced psychologist.
This scale measures the risk for the relative of exhibiting symptoms of post-traumatic stress disorder.
|
3 months after patient's death
|
|
Self-report of the caregiver using the STAI inventory
Time Frame: within 72 hours following the patient's death
|
The caregiver self-assess by responding confidentially to a questionnaire: the STAI inventory (State-Trait Anxiety Inventory).
This questionnaire measures their risk of developing anxiety relating to the event.
|
within 72 hours following the patient's death
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hetero-evaluation of the relative using the HADS anxiety-depression scales
Time Frame: 3 months after patient's death
|
Hetero-evaluation of the relative with the Hospital Anxiety and Depression scales (HADS).
Assessment is performed by telephone interview with an experienced psychologist.
It measures symptoms of anxiety and depression.
|
3 months after patient's death
|
|
Hetero-evaluation of the relative using the CAESAR end-of-life quality scale
Time Frame: 3 months after patient's death
|
Hetero-evaluation of the relative with the CAESAR end-of-life quality scale which assess the quality of end-of-life care in intensive care.
Assessment is performed by telephone interview with an experienced psychologist.
|
3 months after patient's death
|
|
Hetero-evaluation of the relative using the questionnaire survey
Time Frame: 3 months after patient's death
|
Assessment is performed by telephone interview with an experienced psychologist. It consists in a questionnaire of around sixty questions assessing the following themes: progress of the end-of-life process, solicitation / discussion around organ donation, understanding of the process, end-of-life experience, support, relationship with caregivers, questions a posteriori. |
3 months after patient's death
|
|
Hetero-evaluation of the relative using the HADS anxiety-depression scales
Time Frame: 6 months after patient's death
|
Hetero-evaluation of the relative with the Hospital Anxiety and Depression scales (HADS).
Assessment is performed by telephone interview with an experienced psychologist.
It measures symptoms of anxiety and depression.
|
6 months after patient's death
|
|
Hetero-evaluation of the relative using the IES-R scale
Time Frame: 6 months after patient's death
|
Hetero-evaluation of the relative with the IES-R score (Impact of.
Event Scale - Revised score).
Assessment is performed by telephone interview with an experienced psychologist.
This scale measures the risk for the relative of exhibiting symptoms of post-traumatic stress disorder.
|
6 months after patient's death
|
|
Hetero-evaluation of the relative using the PG-13 scale
Time Frame: 6 months after patient's death
|
Hetero-evaluation of the relative with the PG-13 scale (Prolonged Grief Disorder) which measures complicated mourning.
Assessment is performed by telephone interview with an experienced psychologist.
|
6 months after patient's death
|
|
Semi-structured interview with relative
Time Frame: from 6 to 12 months after patient's death
|
20 relatives are selected among the included relatives to undergo a semi-structured interview conducted by an experienced psychologist in order to understand the experience of loved ones, the meaning given to the procedure, the impact of this procedure on the grieving process.
These interviews will be carried out by phone call 6 months after the death within a maximum period of 12 months.
|
from 6 to 12 months after patient's death
|
|
Self-evaluation of the caregiver by questionnaire survey
Time Frame: within 72 hours following the patient's death
|
A 29-question questionnaire is completed confidentially by the caregiver.
The questionnaire addresses the following topics: perception and experience of the withdrawal of life-sustaining therapies (WLST), decision-making process; perception and experience of implementing the decision; perception and experience of soliciting families; experience of the dying process; experience of the role played and involvement of different caregivers during the different stages of the process; difficulties encountered and regrets; elements of satisfaction; aspects to improve.
|
within 72 hours following the patient's death
|
|
Semi-structured interview with caregiver
Time Frame: from 6 to 12 months after patient's death
|
20 caregivers (10 medical staff and 10 paramedical staff and / or until saturation) are selected among the included caregivers in Ile de France to undergo a semi-structured interview conducted by an experienced psychologist.
|
from 6 to 12 months after patient's death
|
Collaborators and Investigators
Investigators
- Study Director: Matthieu LE DORZE, Md, Department of anaesthesiology and critical care medicine. Lariboisiere Hospital.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- APHP200936
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tissue and Organ Procurement
-
Rahmah Health FoundationRawalpindi Medical CollegeCompletedTissue and Organ ProcurementPakistan
-
Centre Hospitalier Universitaire de NīmesCompleted
-
University of HawaiiHealth Resources and Services Administration (HRSA)Completed
-
Case Western Reserve UniversityNational Institute on Minority Health and Health Disparities (NIMHD); Robert...CompletedHealth Behavior | Tissue and Organ ProcurementUnited States
-
Case Western Reserve UniversityTerminatedCommunication | Adolescent Behavior | Tissue and Organ ProcurementUnited States
-
NSW Organ and Tissue Donation ServiceCompletedTissue and Organ ProcurementAustralia
-
Radboud University Medical CenterCompletedTissue and Organ ProcurementNetherlands
-
University of HawaiiNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedTissue and Organ Procurement | Alcohol AbstinenceUnited States
-
University Health Network, TorontoThe Physicians' Services Incorporated Foundation; Trillium Gift of Life Network...UnknownTissue and Organ Procurement
-
Swedish Intensive Care RegistryCompletedTerminal Illness | Decision Making | Tissue and Organ ProcurementSweden
Clinical Trials on Relative section
-
Air Force Military Medical University, ChinaCompletedAcute Leukemia | Childhood Cancer | Cardiac ToxicityChina
-
The University of Texas Health Science Center,...Recruiting
-
University of Santiago de CompostelaCompletedGingival IrritationSpain
-
Asociación Científica Latina A.C.Universidad Autonoma del Estado de MexicoCompletedRheumatoid Arthritis
-
PfizerCompletedHealthy ParticipantsUnited States
-
Zeynep Kamil Maternity and Pediatric Research and...CompletedPain | Hemorrhage | Ileus | Postpartum FeverTurkey
-
Ain Shams UniversityUnknownNatural Cesarean Section
-
University Hospital Inselspital, BerneRecruiting
-
Nazarbayev UniversityCompleted
-
Saint Thomas Hospital, PanamaCompleted